ALD n° 5 - Cardiopathies valvulaires et congénitales graves chez l’adulte - ALD n° 5 - Severe valvular and congenital heart diseases in adults

pages

English

Documents

2008

Écrit par
Has

Publié par
haute-autorite-sante-maladies-cardiaques

Lire un extrait

Obtenez un accès à la bibliothèque pour le consulter en ligne En savoir plus

Découvre YouScribe et accède à tout notre catalogue !

Je m'inscris

Découvre YouScribe et accède à tout notre catalogue !

Je m'inscris

pages

English

Documents

2008

Lire un extrait

Obtenez un accès à la bibliothèque pour le consulter en ligne En savoir plus

Publié par

haute-autorite-sante-maladies-cardiaques

Publié le

01 juin 2008

Nombre de lectures

Licence :

En savoir +

Langue

English

Posted on Jul 21 2008 The aim of this guide for medical practitioners is to describe the optimal theorical care and the clinical pathway for a patient entering the ALD [Long term condition] scheme, severe valvular heart disease. The aim of this guide for medical practitioners is to describe the optimal theorical care and the clinical pathway for a patient entering the ALD [Long term condition] scheme, severe valvular heart disease. Posted on Jul 21 2008

Voir

Publié par

haute-autorite-sante-maladies-cardiaques

Publié le

01 juin 2008

Licence :

En savoir +

Langue

English

LONG-TERM CONDITIONS GUIDE

Severe valvular and congenital heart diseases in adults

June 2008

This doctors’ guide is available for download at www.has-sante.fr

Haute Autorité de Santé Communication Department 2, avenue du Stade-de-France F 93218 Saint-DenisLa Plaine Cedex Phone: +33 (0)1 55 93 70 00 - Fax: +33 (0)1 55 93 74 00

This document was validated by the HAS Board in June 2008. © Haute Autorité de Santé 2008

ALD Guide for doctors Severe valvular and congential heart diseases in adults

Contents

List of abbreviations ...........................................................................3

Introduction

1. 1.1 1.2 1.3 1.4 1.5 1.6 1.7

2. 2.1 2.2 2.3 2.4 2.5 2.6 2.7

...............................................................................6

Initial assessment .....................................................................8

Objectives ............................................................................ 8 Professionals involved ........................................................ 8 Diagnosis ............................................................................. 8 Complementary tests ........................................................ 10 Risk of infectious endocarditis assessment...................... 11 Thromboembolic risk assessment .................................... 11 Specific case of pregnant women or women wishing to become pregnant .............................................................. 12

Therapeutic management .......................................................13

Objectives .......................................................................... 13 Professionals involved ...................................................... 13 Self management education ............................................. 14 Pharmacological treatments ............................................. 15 Invasive treatment ............................................................. 18 Procedure in the event of non-cardiac surgery ................ 20 Implantable medical devices............................................. 21

3. Follow-up .............................................................................23 3.1 Objectives .......................................................................... 23 3.2 Professionals involved ...................................................... 23 3.3 Clinical monitoring ............................................................. 25 3.4 Additional tests .................................................................. 25

Appendix 1. Participants .................................................................27

Appendix 2. Target INR in the case of a mechanical prosthesis ......28

Appendix 3. Self-measurement and self-monitoring in the case of VKA treatment ........................................................................29

HAS / Department of Chronic Diseases and Patient Support June 2008

-1-